

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



China Health Group Limited
中國衛生集團有限公司

(Carrying on business in Hong Kong as CHG HS Limited)

(Incorporated in Bermuda with limited liability)

(Stock Code: 673)

ANNOUNCEMENT IN RESPECT OF A WRIT OF SUMMONS
ISSUED BY THE COMPANY

This announcement is made by the board of directors (the “**Board**”) of China Health Group Limited (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

On 6 September 2022, a writ of summons under the action number HCA 1148/2022 has been issued in the High Court of the Hong Kong Special Administrative Region (“**Writ**”) by the Company against Chiu & Partners (a firm) (the “**Defendant**”) which was engaged as the legal representative of the Company from around December 2015 to June 2016.

Pursuant to the Writ, the Company claims against the Defendant for its breach of duty of care in relation to its negligent handling of several proceedings in the High Court of the Hong Kong Special Administrative Region and the Supreme Court of Bermuda (Civil Division) involving the Company at the material time, and its breach of fiduciary duties to act bona fide in the best interests of the Company. The Company claims the Defendant for, amongst others, damages for breach of duty of care to be assessed, equitable compensation for breach of fiduciaries duties, together with interest, costs and/or other relief.

Further announcement(s) will be made by the Company as and when appropriate to keep the shareholders of the Company and potential investors informed of the material developments in relation to the above.

By order of the Board
China Health Group Limited
Zhang Fan

Chairman of the Board and Executive Director

Hong Kong, 9 September 2022

As at the date of this announcement, the Board comprises two executive Directors, namely, Mr. Zhang Fan (chairman) and Mr. Chung Ho; three non-executive Directors, namely, Mr. Xing Yong, Mr. Huang Lianhai and Mr. Wang Jingming; and three independent non-executive Directors, namely, Mr. Jiang Xuejun, Mr. Du Yanhua and Mr. Lai Liangquan.